Neuropsychological predictors of response to randomized treatment in obsessive-compulsive disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 2, 2012, Pages 310-317

  D'Alcante, Carina C ^a   Diniz, Juliana B ^a   Fossaluza, Victor ^a   Batistuzzo, Marcelo C ^a   Lopes, Antonio C ^a   Shavitt, Roseli G ^a   Deckersbach, Thilo ^b   Malloy Diniz, Leandro ^c   Miguel, Euripedes C ^a   Hoexter, Marcelo Q ^a,d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cognitive behavioral therapy; Neuropsychology; Obsessive compulsive disorder; Serotonin reuptake inhibitors; Treatment na ve

Indexed keywords

FLUOXETINE;

ADULT; ARTICLE; CALIFORNIA VERBAL LEARNING TEST; CLINICAL ARTICLE; COGNITION; COGNITIVE THERAPY; CONTROLLED STUDY; DRUG DOSE INCREASE; EXECUTIVE FUNCTION; FEMALE; HUMAN; INTELLECT; INTELLIGENCE QUOTIENT; MALE; MENTAL FUNCTION; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERBAL MEMORY; VICTORIA STROOP TEST; WECHSLER INTELLIGENCE SCALE;

ADOLESCENT; ADULT; AGED; COGNITIVE THERAPY; FEMALE; FLUOXETINE; HUMANS; INTELLIGENCE TESTS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OBSESSIVE-COMPULSIVE DISORDER; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84867006281     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.07.002     Document Type: Article

References (65)

1. Bechara A., Damásio A.R., Damásio H., Anderson S.W. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 1994, 50(1-3):7-15.
2. Beck J.S. Cognitive therapy: basics and beyond 1995, Guilford, New York.
3. Beck A.T., Ward C.H., Mendelson M., Mock J, Erbaugh G. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
4. Beck A.T., Epstein N., Brown G., Steer R.A. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988, 56:893-897.
5. Belotto-Silva C., Diniz J.B., Malavazzi D.M., Valério C., Fossaluza V., Borcato S., et al. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. J Anxiety Disord 2012, 26(1):25-31. [ Jan] [Epub 2011 Aug 19].
6. Benedict R. Brief visual memory test - revised: professional manual 1997, Psychological Assessment Resources, Inc., Odessa.
7. Bérdard M.J., Joyal C.C., Godbout L., Chantal S. Executive functions and the obsessive-compulsive disorder: on the importance of subclinical symptoms and other concomitant factors. Arch Clin Neuropsychol 2009, 24(6):585-598. Se.
8. Bespalov A.Y., van Gaalen M.M., Gross G. Antidepressant treatment in anxiety disorders. Curr Top Behav Neurosci 2010, 2:361-390.
9. Bolton D., Raven P., Madronal-Luque R., Marks I.M. Neurological and neuropsychological signs in obsessive compulsive disorder: interaction with behavioural treatment. Behav Res Ther 2000, 38(7):695-708. (Jul).
10. Buitelaar J.K., Van der Gaag R.J., Swaab-Barneveld H., Kuiper M. Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995, 34(8):1025-1032. (Aug).
11. Burgess P., Shallice T. The Hayling and Brixton tests 1997, Thames Valley Test Company, Bury St Edmunds.
12. Cavedini P., Riboldi G., D'Annucci A., Belotti P., Cisima M., Bellodi L. Decision-making heterogeneity in obsessive-compulsive disorder: ventromedial prefrontal cortex function predicts different treatment outcomes. Neuropsychologia 2002, 40:205-211.
13. Chamberlain S., Blackwell A., Fineberg N., Robbins T., Sahakian B. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev 2005, 29(3):399-419. (May).
14. Delis D., Kramer J., Kaplan E., Ober B. California verbal learning test 2000, The Psychological Corporation, San Antonio. 2nd edition ed.
15. El Mansari M., Blier P. Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(3):362-373. May.
16. Ferrão Y.A., Shavitt R.G., Bedin N.R., de Mathis M.E., Lopes A.Carlos, Fontenelle L.F., et al. Clinical features associated to refractory obsessive-compulsive disorder. J Affect Disord 2006, 94(1-3):199-209. (Aug).
17. Fineberg N., Gale T. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2005, 8(1):107-129. (Mar).
18. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I disorders - patient edition (SCID-I/P, version 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York, NY.
19. Flessner C.A., Allgair A., Garcia A., Freeman J., Sapyta J., Franklin M.E., et al. The impact of neuropsychological functioning on treatment outcome in pediatric obsessive-compulsive disorder. Depress Anxiety 2010, 27(4):365. (Apr).
20. Foa E., Liebowitz M., Kozak M., Davies S., Campeas R., Franklin M., et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005, 162(1):151-161. (Jan).
21. Fontenelle L., Marques C., Engelhardt E., Versiani M. Impaired set-shifting ability and therapeutic response in obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 2001, 13(4):508-510.
22. Fontenelle L.F., Mendlowic M.V., Marques C., Versiani M. Early- and late-onset obsessive-compulsive disorder in adult patients: exploratory clinical and therapeutic study. J Psychol Res 2003, 37:127-133.
23. Fossaluza V., Diniz J.B., Pereira BeB, Miguel E.C., Pereira C.A. Sequential allocation to balance prognostic factors in a psychiatric clinical trial. Clinics (Sao Paulo) 2009, 64(6):511-518.
24. Freedman M. Object alternation and orbitofrontal system dysfunction in Alzheimer's and Parkinson's disease. Brain Cogn 1990, 14(2):134-143. (Nov).
25. Ginsburg G.S., Kingery J.N., Drake K.L., Grados M.A. Predictors of treatment response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2008, 47(8):868-878. (Aug).
26. Gorenstein E.E., Papp L.A. Cognitive-behavioral therapy for anxiety in the elderly. Curr Psychiatry Rep 2007, 9(1):20-25. (Feb).
27. Heaton R. Wisconsin card sorting test manual 1981, Psychological Assessment Resources, Inc., Odessa.
28. Hoexter M.Q., Shavitt R., D'Alcante C.C., Cecconi J., Diniz J., Belotto-Silva C., et al. The drug-naïve OCD patients imaging genetics, cognitive and treatment response study: methods and sample description. Rev Bras Psiquiatr 2009, 31(4):349-353. (Dec).
29. Hoexter M.Q., de Souza Duran F.L., D'Alcante C.C., Dougherty D.D., Shavitt R.G., Lopes A.C., et al. Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial. Neuropsychopharmacology 2012, 37(3):734-745. (Feb).
30. Hollander E., Wong C.M. The relationship between executive function impairment and serotonergic sensitivity in obsessive-compulsive disorder. Neuropsychiatry Neuropsychol Behav Neurol 1996, 9:230-233.
31. Kang D.H., Kwon J.S., Kim J.J., You T., Park H.J., Kim M.S., et al. Brain glucose metabolic changes associated with neuropsychological improvements after 4months of treatment in patients with obsessive-compulsive disorder. Acta Psychiatr Scand 2003, 107:291-297.
32. Kim M.S., Park S.J., Shin M.S., Kwon J.S. Neuropsychological profile in patients with obsessive-compulsive disorder over a period of 4-month treatment. J Psychiatr Res 2002, 36:257-265.
33. Koran L. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am 2000, 23(3):509-517. (Sep).
34. Krishna R., Udupa S., George C.M., Kumar K.J., Viswanath B., Kandavel T., et al. Neuropsychological performance in OCD: a study in medication-naïve patients. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(8):1969-1976. (Dec 1).
35. Kuelz A.K., Hohagen F., Voderholzer U. Neuropsychological performance in obsessive-compulsive disorder: a critical review. Biol Psychol 2004, 65(3):185-236. (Feb).
36. Kuelz A.K., Riemann D., Halsband U., Vielhaber K., Unterrainer J., Kordon A., et al. Neuropsychological impairment in obsessive-compulsive disorder-improvement over the course of cognitive behavioral treatment. J Clin Exp Neuropsychol 2006, 28(8):1273-1287. (Nov).
37. Lennertz L., Rampacher F., Vogeley A., Schulze-Rauschenbach S., Pukrop R., Ruhrmann S., et al. Antisaccade performance in patients with obsessive-compulsive disorder and unaffected relatives: further evidence for impaired response inhibition as a candidate endophenotype. Eur Arch Psychiatry Clin Neurosci 2012, 23. (Mar).
38. Leon A., Portera L., Weissman M. The social costs of anxiety disorders. Br J Psychiatry Suppl 1995, 27:19-22. (Apr).
39. Maher M.J., Huppert J.D., Chen H., Duan N., Foa E.B., Liebowitz M.R., et al. Moderators and predictors of response to cognitive-behavioral therapy augmentation of pharmacotherapy in obsessive-compulsive disorder. Psychol Med 2010, 40(12):2013-2023. Dec.
40. Mataix-Cols D., Rauch S.L., Manzo P.A., Jenike M.A., Baer L. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 1999, 156(9):1409-1416. (Sep).
41. Mccullagh P., Nelder J.A. Generalized linear models 1989, Chapman and Hall, London.
42. McDougle C.J., Goodman W.K., Price L.H. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychol 1990, 147:652-654. (19).
43. Menzies L., Chamberlain S.R., Laird A.R., Thelen S.M., Sahakian B.J., Bullmore E.T. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev 2008, 32(3):525-549.
44. Miguel E.C., Ferrão Y.A., Rosário M.C., Mathis M.A., Torres A.R., Fontenelle L.F., et al. The Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders: recruitment, assessment instruments, methods for the development of multicenter collaborative studies and preliminary results. Rev Bras Psiquiatr 2008, 30(3):185-196. (Sep).
45. Moritz S., Kloss M., Jacobsen D., Fricke S., Cutler C., Brassen S., et al. Neurocognitive impairment does not predict treatment outcome in obsessive-compulsive disorder. Behav Res Ther 2005, 43(6):811-819. (Jun).
46. Olley G., Malhi P., Sachdev Memory and executive functioning in obsessive-compulsive disorder: a selective review. J Affect Disord 2007, 104:15-23.
47. Osterrieth P. Le test de copie d'une figure complexe: contribution a l'e'tude de la perception et de la memoire. Arch Psychol 1944, 30:286-350.
48. Pallanti S., Hollander E., Bienstock C., Koran L., Leckman J., Marazziti D., et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002, 5(2):181-191. (Jun).
49. Park S., Shin M., Kwon J. Neuropsychological profile in patients with obsessive-compulsive disorder over a period of 4-month treatment. J Psychiatr Res 2002, 36(4):257-265. (Jul-Aug).
50. Rajender G., Bhatia M.S., Kanwal K., Malhotra S., Singh T.B., Chaudhary D. Study of neurocognitive endophenotypes in drug-naïve obsessive-compulsive disorder patients, their first-degree relatives and healthy controls. Acta Psychiatr Scand 2011, 124(2):152-161. (Aug, Epub 2011 Jun 16). 10.1111/j.1600-0447.2011.01733.x.
51. Ravizza L., Barzega G., Bellino S., Bogetto F., Maina G. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 1995, 56(8):368-373. (Aug).
52. Regard M. Cognitive rigidity and flexibility: a neuropsychological study 1981, University of Victoria, Victoria.
53. Rosário-Campos M.C., Leckman J., Mercadante M. Adults with early-onset obsessive-compulsive disorder. Am J Psychol 2001, 158:1899-1903.
54. Rosário-Campos M.C., Miguel E.C., Quatrano S., Chacon P., Ferrao Y., Findley D., et al. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. Mol Psychiatry 2006, 11(5):495-504.
55. Ruscio A., Stein D., Chiu W., Kessler R. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010 Jan, 15(1):53-63.
56. Ruscio A.M., Stein D.J., Chiu W.T., Kessler R.C. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010 Jan, 15(1):53-63.
57. Shavitt R.G., Belotto C., Curi M., Hounie A.G., Rosário-Campos M.C., Diniz J.B., et al. Clinical features associated with treatment response in obsessive-compulsive disorder. Compr Psychiatry 2006, 47(4):276-281. (Jul-Aug).
58. Shin N.Y., Kang D.H., Choi J.S., Jung M.H., Jang J.H., Kwon J.S. Do organizational strategies mediate nonverbal memory impairment in drug-naïve patients with obsessive-compulsive disorder?. Neuropsychology 2010, 24(4):527-533. (Jul).
59. Simpson H.B., Rosen W., Huppert J.D., Lin S.H., Foa E.B., Liebowitz M.R. Are there reliable neuropsychological deficits in obsessive-compulsive disorder?. J Psychiatr Res 2006, 40:247-257.
60. Spreen O., Strauss E. A compendium of neuropsychological tests: administration, norms and commentary 1998, Oxford University Press, New York. 2nd edition.
61. Thienemann M., Koran M.K. Do soft signs predict treatment outcome in obsessive-compulsive disorder?. J Neuropsychiatry Clin Neurosci 1995, 7:218-222.
62. Wechsler D. Wechsler adult intelligence scale 1997, Psychological Corporation, San Antonio.
63. Wechsler D. Wechsler memory scale 1997, The Psychological Corporation, San Antonio, TX. 3rd edition.
64. Wechsler D. The Wechsler abbreviated scale of IQ 1999, Psychological Corporation/ Harcourt Brace and Company, San Antonio.
65. Weissman M.M., Bland R.C., Canino G.J., Greenwald S., Hwu H.G., Lee C.K., et al. The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry 1994, 55 (Suppl.):5-10.